Search Results - "Megna, Matteo"

Author reply to 'Comment on ChatGPT and medical writing in dermatology: why should we keep writing?'.

Authors: Potestio, Luca Megna, Matteo Cacciapuoti, Sara et al.

Source: Clinical & Experimental Dermatology. Nov2024, Vol. 49 Issue 11, p1428-1428. 1p.

Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?'.

Authors: Ruggiero, Angelo Megna, Matteo Caiazzo, Giuseppina et al.

Source: Clinical & Experimental Dermatology. Apr2023, Vol. 48 Issue 4, p396-397. 2p.

Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes—IL PSO (Italian Landscape Psoriasis).

Authors: Ibba, Luciano Di Giulio, Sara Malagoli, Piergiorgio et al.

Source: Dermatology & Therapy. Apr2026, Vol. 16 Issue 4, p2169-2180. 12p.

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study.

Authors: Torres, Tiago Sood, Siddhartha Yilmaz, Orhan et al.

Source: Dermatology & Therapy. Feb2026, Vol. 16 Issue 2, p701-707. 7p.

The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study.

Authors: Cacciapuoti, Sara Megna, Matteo Salza, Emanuela et al.

Source: Journal of Dermatological Treatment. Dec2024, Vol. 35 Issue 1, p1-3. 3p.

Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.

Authors: Megna, Matteo Ruggiero, Angelo Torta, Ginevra et al.

Source: Clinical & Experimental Dermatology. Oct2024, Vol. 49 Issue 10, p1186-1189. 4p.

ChatGPT and medical writing in dermatology: why should we keep writing?

Authors: Potestio, Luca Megna, Matteo Cacciapuoti, Sara et al.

Source: Clinical & Experimental Dermatology. Aug2024, Vol. 49 Issue 8, p929-930. 2p.

CorrespondenceAuthor reply to 'Comment on ChatGPT and medical writing in dermatology: why should we keep writing?' by Duff et al.

Authors: Potestio, Luca Megna, Matteo Cacciapuoti, Sara et al.

Source: Clinical & Experimental Dermatology. Nov2024, Vol. 49 Issue 11, p1427-1427. 1p.

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Authors: Bernardini, Nicoletta Dattola, Annunziata Gemma, Giuseppe Paolo Antonio et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-6. 6p.

Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.

Authors: Megna, Matteo Balato, Anna Caccavale, Stefano et al.

Source: Journal of Clinical Medicine. May2024, Vol. 13 Issue 9, p2552. 9p.

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Authors: Gargiulo, Luigi Costanzo, Antonio Malagoli, Piergiorgio et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3331-3344. 14p.

A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab.

Authors: Megna, Matteo Battista, Teresa Potestio, Luca et al.

Source: Journal of Cosmetic Dermatology. Mar2023, Vol. 22 Issue 3, p1146-1148. 3p.

Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient.

Authors: Megna, Matteo Abategiovanni, Luisa Annunziata, Alberto et al.

Source: Dermatologic Therapy. May2022, Vol. 35 Issue 5, p1-4. 4p.

Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis.

Authors: Scala, Emanuele Megna, Matteo Amerio, Paolo et al.

Source: PLoS ONE. 8/12/2020, Vol. 15 Issue 8, p1-14. 14p.

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab.

Authors: Megna, Matteo Marano, Laura Camela, Elisa et al.

Source: Dermatologic Therapy. Oct2022, Vol. 35 Issue 10, p1-3. 3p.

A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?

Authors: Ruggiero, Angelo Megna, Matteo Marino, Vincenzo et al.

Source: Dermatologic Therapy. Apr2022, Vol. 35 Issue 4, p1-3. 3p.

Ciprofloxacin‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient.

Authors: Megna, Matteo Camela, Elisa Ocampo Garza, Sonia S. et al.

Source: Contact Dermatitis (01051873). Oct2021, Vol. 85 Issue 4, p467-469. 3p.

Immune response to COVID‐19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics.

Authors: Megna, Matteo Potestio, Luca Battista, Teresa et al.

Source: Clinical & Experimental Dermatology. Dec2022, Vol. 47 Issue 12, p2310-2312. 3p. 1 Chart.

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab.

Authors: Megna, Matteo Genco, Lucia Noto, Matteo et al.

Source: Dermatologic Therapy. Nov2022, Vol. 35 Issue 11, p1-3. 3p.

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study.

Authors: Megna, Matteo Ruggiero, Angelo Battista, Teresa et al.

Source: Journal of Clinical Medicine. May2023, Vol. 12 Issue 9, p3233. 10p.